Eyegate Pharmaceuticals (NASDAQ:EYEG) issued its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01, Bloomberg Earnings reports. The business had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.19 million.

NASDAQ EYEG traded up $0.01 during trading on Wednesday, hitting $0.43. The stock had a trading volume of 4,720,632 shares, compared to its average volume of 683,226. The company has a market cap of $13.55 million, a P/E ratio of -0.42 and a beta of 2.92. Eyegate Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $1.38.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Eyegate Pharmaceuticals in a research report on Wednesday, September 5th.

COPYRIGHT VIOLATION NOTICE: “Eyegate Pharmaceuticals (EYEG) Releases Earnings Results, Beats Expectations By $0.01 EPS” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.dailypolitical.com/2018/11/14/eyegate-pharmaceuticals-eyeg-releases-earnings-results-beats-expectations-by-0-01-eps.html.

Eyegate Pharmaceuticals Company Profile

EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Earnings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.